The efficacy and safety of cilostazol as an alternative to aspirin in Chinese patients with aspirin intolerance after coronary stent implantation: a combined clinical study and computational system pharmacology analysis Abstract Dual antiplatelet therapy (DAT) with aspirin and clopidogrel is the standard regimen to achieve rapid platelet inhibition and prevent thrombotic events. Currently, little information is available regarding alternative antiplatelet therapy in patients with an allergy or intolerance to aspirin. Although cilostazol is already a common alternative to aspirin in clinical practice in China, its efficacy and safety remain to be determined. We retrospectively analyzed 613 Chinese patients who had undergone primary percutaneous coronary intervention (PCI). Among them, 405 patients received standard DAT (aspirin plus clopidogrel) and 205 patients were identified with intolerance to aspirin and received alternative DAT (cilostazol plus clopidogrel). There were no significant differences between the two groups in their baseline clinical characteristics. The main outcomes of the study included major adverse cardiac events (MACEs) and bleeding events during 12 months of follow-up. The MACEs endpoint was reached in 10 of 205 patients treated with cilostazol (4.9%) and in 34 of 408 patients treated with aspirin (8.3%). No statistically significant difference was observed in MACEs between the two groups. However, patients in the cilostazol group had less restenosis than did patients in the aspirin group (1.5% vs 4.9%, P=0.035). The occurrence of bleeding events tended to be lower in the cilostazol group (0.49% vs 2.7%, P=0.063). These clinical observations were further analyzed using network system pharmacology analysis, and the outcomes were consistent with clinical observations and preclinical data reports. We conclude that in Chinese patients with aspirin intolerance undergoing coronary stent implantation, the combination of clopidogrel with cilostazol may be an efficacious and safe alternative to the standard DAT regimen.
Introduction
Although drug-eluting stents (DES) have decreased the incidence of restenosis and repeat revascularization in patients undergoing percutaneous coronary intervention (PCI), information is available regarding alternative antiplatelet therapy in patients with an intolerance to aspirin. Therefore, the optimal regimen of antiplatelet therapy in such patients has become a problem to be solved.
Cilostazol is a selective inhibitor of phosphodiesterase type III (PDE3) that inhibits platelet aggregation in response to adenosine diphosphate (ADP), epinephrine, collagen, and arachidonic acid [11] . It has been reported that the adjunctive use of cilostazol can overcome limitations of DES, with respect to both thrombosis and restenosis [12] [13] [14] . In addition, cilostazol is expected to have potential for achieving the critical balance between hemorrhagic risk and antiplatelet efficacy in patients with thrombotic disease and bleeding risk [15] [16] . Hence, cilostazol is considered an alternative to aspirin in real-world clinical practice in China. However, its efficacy and safety remains to be determined, particularly for patients after coronary stent implantation [17] . The present work aimed to study the efficacy and safety of cilostazol as an alternative to aspirin after coronary stent implantation in patients with intolerance to aspirin. The clinical observations were further analyzed by computational system pharmacology.
Materials and methods

Study design and patients
This study was a retrospective cohort analysis of 613 consecutive patients who underwent coronary stent implantation between July 2014 and July 2015 at Zhongshan Hospital. A total of 205 patients were identified with intolerance to aspirin and received alternative DAT. Our Medical Ethics Committee approved this study and waived the requirement for informed consent. Aspirin intolerance was defined as follows: i) a documented allergic reaction to aspirin; ii) patient's or referring physician's unwillingness to take or prescribe aspirin because of prior side effects and/or recurrent symptoms despite treatment with a proton pump inhibitor. Reasons for not taking aspirin included gastrointestinal intolerance (82.4%), allergy (6.8%), non-gastrointestinal bleeding (2.9%) and other reasons (7.8%). The aspirin-intolerant patients were treated with cilostazol in combination with clopidogrel as an alternative DAT regimen.
All patients had angina pectoris or a positive stress test and had native coronary artery lesions for which DES implantation was feasible. Patients were excluded if they had contraindications to clopidogrel or cilostazol; an age less than 18 years; a left ventricular ejection fraction <30%; a platelet count <100 000/mm 3 ; severe liver and kidney insufficiency; or acute or chronic infection.
Medication and PCI procedure
All patients received drug-eluting stents and dual antiplatelet therapy. At least 24 h before the procedure, a loading dose of 300 mg clopidogrel was administered, and a daily regimen of 75 mg was prescribed for 12 months. Patients in the control group received a 300 mg loading dose followed by a daily regimen of 100 mg. Patients in the study group received cilostazol (50 mg twice daily). The dose of cilostazol (100 mg/d) in the present study is the dose commonly used in our institution. Procedural details, including use of anticoagulation drugs and type of stents, were dependent upon the operators. All patients received a successful PCI.
Clinical endpoints
Major adverse cardiac events were defined as the composite of all-cause death, non-fatal myocardial infarction (MI), restenosis, target vessel revascularization (TVR) and stroke. Non-fatal myocardial infarction was defined as recurrent symptoms with new ST-segment elevation or re-elevation of cardiac markers to at least twice the upper limit of normal. TVR was defined as any repeat revascularization of the target vessel. Stroke was defined as persistent loss of neurological function developed after primary PCI and an acute lesion identified with magnetic resonance imaging (MRI). Bleeding was classified according to the Bleeding Academic Research Consortium (BARC) classification. Cases with a BARC score >2 were recorded [18] .
Collection of demographic, medical, and laboratory data Demographic and medical data, including age, sex and comorbid conditions, were obtained from medical records or patient interviews. The body mass index (BMI) was calculated for each subject as the ratio of the weight in kilograms divided by the square of the height in meters. Blood pressure was measured in the supine position using a mercury sphygmomanometer with an appropriate cuff on the left arm; the average of two readings was used for the statistical analysis.
A 12-h overnight fasting venous blood sample was collected for measurements of hemoglobin, hematocrit, creatinine, alanine transaminase and platelets.
C V D P l a t f o r m -c a r d i ova s c u l a r d i s e a s e ( C V D ) -s p e c i f i c chemogenomics database
We have constructed a cardiovascular disease (CVD)-specific chemogenomics database [19] that can be used for target/offtarget (or additional) identification and network system pharmacology analysis of small molecules and their potential targets. Several in-house chemoinformatics tools were also used, including TargetHunter, HTDocking, Blood−Brain Barrier (BBB) Predictor (developed by Xie's laboratory, Pittsburgh, PA, USA), etc [20] [21] [22] [23] [24] [25] [26] . CVDPlatform (www.cbligand.org/CVD) archived 984 CVD-related target proteins, 924 approved CVD drugs in clinical trials, 2080 active chemical compounds associated with the therapeutic targets of CVD, 276 cardiovascularrelated pathways, and 350 765 references.
In the present work, we applied our CVDPlatform and HTDocking program to perform the network system pharmacological analysis of small molecules, including aspirin and cilostazol. Cytoscape 3.4.0 was used to generate, analyze and visualize the graphical network between targets and drug/ compounds, as described previously [19] .
Statistical analysis
Data are presented as the mean±SD for continuous variables 
Results
Baseline characteristics
Baseline clinical characteristics of the 613 patients are presented in Table 1 . There were no significant differences in age, sex, or cardiovascular risk factors between the two groups. Medication profiles were not different between the two groups.
Lesion and procedural characteristics are shown in Table 2 . The two groups had similar baseline angiographic and PCI procedural characteristics.
Clinical outcomes
Clinical follow-up for 12 months was obtained in all patients.
The clinical outcomes are summarized in Table 3 . The efficacy endpoints, composite of death, MI, ischemic stroke, restenosis and TVR occurred in 10 patients (4.9%) in the study group and 34 patients (8.3%) in the control group, and the results were not significantly different (OR 0.56; 95% CI=0.27-1.17; P=0.12) (Table 3) . MI, ischemic stroke and TVR also did not appear to differ significantly between the two study groups. However, the restenosis rate was statistically lower in groups treated with cilostazol than the control group (1.5% vs 4.9%; OR 0.29; 95% CI=0.09-0.98; P=0.035). The incidence of bleeding tended to be lower in the study group (0.49% vs 2.7%; OR 0.18; 95% CI = 0.02-1.38; P=0.063).
Network systems pharmacology studies We applied our constructed CVDPlatform (www.cbligand. org/CVD) and our network system pharmacology approach to predict and analyze the complex interactions between aspirin/cilostazol and cardiovascular-related target proteins. Our high-throughput molecular docking (www.CBLigand.org/ HTdocking) approach was used to map out the predicted interactions between aspirin/cilostazol and 984 target proteins in CVDPlatform. Briefly, the drug molecules were docked into the pocket of the target protein by using AutoDock Vina. We then ranked the potential cardiovascular therapeutic protein targets to specific drug according to the docking scores. Top listed targets with higher docking scores may have higher binding affinities or a greater chance of interacting with our input compounds. Subsequently, we mapped out a pharmacological network of interactions between drug compounds and target proteins at the molecular level.
As shown in Figure 1 , the potential (or additional) target proteins of these two drugs were predicted and ranked on the basis of docking scores (cut-off value: 6.5) with the interaction network. Interestingly, our results showed that most of the docking scores of target proteins for cilostazol were higher than that for aspirin (Table 4 ). This result is reasonable because cilostazol fits better into the pockets of target proteins, owing to its flexible structure and stronger interactions. Moreover, our predicted results correlate well with the known therapeutic targets of aspirin and cilostazol (higher docking scores). For example, prostaglandin G/H synthase 1/prostaglandin G/H synthase 2 (gene name: COX1/COX2), cytochrome P450 1A2 (gene name: CYP1A2), and serum albumin (gene name: ALB) ranked first/twelfth, fourth and sixth, respectively, in the list of aspirin target proteins. Several recent literature reports have found that the the IC 50 for aspirin toward COX1/COX2 is 0.3/2.4 µmol/L, respectively [27] [28] . The docking scores (mean value from two independent docking runs) for aspirin toward COX1 and COX2 showed differences in our computational work, in which the docking scores of COX1 and COX2 were 8.1 and 6.7, respectively, thus indicating that the docking study was sufficiently sensitive to reflect their different binding affinities. cGMP-inhibited 3',5'-cyclic phosphodiesterase A (gene name: PDE3A) ranked eleventh in the list of cilostazol target proteins. Three additional shared targets for these two drugs were also validated by bioassays, including angiotensin II type-2 (AT2) receptor (gene name: AGTR2), angiotensin-converting enzyme (gene name: ACE), and cathepsin G (gene name: CTSG).
Discussion
To the best of our knowledge, this study is the first to investigate the efficacy and safety of cilostazol as a substitute for aspirin. In the present work, we performed a retrospective study to analyze the clinical outcomes in 205 of 613 patients undergoing coronary stent implantation who were treated with cilostazol as an alternative antiplatelet agent to aspirin. The statistical analysis results revealed that cilostazol, compared with aspirin, has the potential to decrease restenosis events, and the occurrence of bleeding events tended to be lower in the cilostazol group. No significant difference was observed in MACEs between the two groups. The main finding of the present study was that in aspirin-intolerant patients undergoing coronary stent implantation, the combination of cilostazol with clopidogrel appeared well tolerated and effective.
To better understand the outcome analysis results of the clinical observation above, we carried out a molecular network system pharmacology (MSP) investigation by using our estab- lished cardiovascular disease-domain specific chemogenomics knowledgebase, TargetHunter and HTDocking programs. We analyzed the complex interactions of aspirin and cilostazol with cardiovascular-related target proteins in biological systems. The results were consistent with clinical observations, showing that cilostazol has additional protein targets that may explain its superior effect on prevention of restenosis and lower risk of bleeding. The combined clinical data-mining and system pharmacology studies also provide a promising approach to better understand the outcomes of cilostazol as an alternative antiplatelet agent to aspirin at both the clinical and molecular levels.
Although the combination of aspirin and one of the P2Y purinoceptor 12 (P2Y12) inhibitors (such as clopidogrel) is recommended as standard dual antiplatelet therapy after percutaneous coronary intervention, patients with a prior history of an aspirin "reaction" are routinely denied this standard DAT. Several studies have suggested the need for an alternative regimen for patients with aspirin intolerance [29] [30] . Thus, an optimal regimen of antiplatelet therapy for those patients is continually evolving.
Cilostazol is a cAMP PDE-III inhibitor that exerts a strong antithrombotic effect not only by directly inhibiting platelet function but also by decreasing the number of activated circulating platelets while maintaining a minimal risk of bleeding [15, [31] [32] . In Asian countries, cilostazol is widely used as an antiplatelet agent for the secondary prevention of ischemic events, and it is often preferred over aspirin or thienopyridines, owing to its comparable efficacy and more favorable safety profile [15, 33] . In fact, cilostazol has been shown to be associated with decreased bleeding risk, as compared with other antiplatelet agents. In addition, cilostazol also decreases neointimal proliferative reactions after coronary stent implantation [14, [34] [35] [36] [37] [38] [39] [40] . In clinical studies, cilostazol-based triple antiplatelet treatment (TAPT) has been found to have the potential to decrease major adverse cardiac events and stent thrombosis without increasing the risk of bleeding [33] [34] [35] [36] 40] . The known pharmacological action of cilostazol on inhibiting platelet activation and aggregation, as well as the proven anti-ischemic effects demonstrated above, has provided a rationale for clinicians to use cilostazol after stent implantation in the rare subset of patients who are intolerant or allergic to aspirin. However, in clinical practice, little information is available on whether cilostazol may be a successful alternative antiplatelet therapy for these patients.
Our retrospective study demonstrated that cilostazol has comparable efficacy to aspirin in preventing MACEs after stent implantation. It has been reported that cilostazol, compared with aspirin, has the potential to decrease restenosis after balloon angioplasty, stent implantation, and directional coronary atherectomy [12] [13] [14] [41] [42] . In line with results from previous studies, in this study, the use of cilostazol, compared with aspirin, resulted in a lower rate of restenosis in coronary artery disease patients. Patients with a prior history of aspirin intolerance are often at higher risk of gastrointestinal bleeding. Our results suggested that cilostazol, as an alternative for aspirinintolerant patients, did not increase the risk of bleeding (0.49% in cilostazol group vs 2.7% in the aspirin group, P=0.063).
Using a molecular systems pharmacology approach, we mapped out the potential molecular targets for aspirin and cilostazol in addition to those known drug targets. The system pharmacology predictions were consistent with clinical observations and preclinical data reports. A multi-target drug is a compound that can modulate multiple proteins. For example, after aspirin molecules enter the cell, most will act on major targets (for example, COX1 or COX2). However, others may also act on other targets (ie, off-target effects), which may generate either therapeutic effects or side effects. Thus, computational system pharmacology studies can be used to identify other potential CVD-related targets associated with aspirin, in addition to COX1/COX2, and with cilostazol, in addition to PDE3A. Importantly, our system pharmacology predictions indicated that cilostazol showed synergetic benefits for: (1) anti-bleeding effect by acting on the angiotensin II type-1 (AT1) receptor (gene name: AGTR1) and (2) prevention of restenosis by targeting proteinase-activated receptor 4 (PAR4) (gene name: F2RL3) and/or P2Y purinoceptor 12 (P2Y12) (gene name: P2RY12), which are among the top predicted targets for cilostazol (Figure 1 , P2Y12 PDB: 4NTJ) [43] . Schindler et al have reported that, using the AT1-receptor antagonist candesartan in patients with severe atherosclerosis after superficial femoral artery stenting produces a significantly better effect against restenosis than the treatment with the ACE inhibitor quinapril [44] . Goel et al have found that Ticagrelor, a P2Y12 antagonist, prevents restenosis by inhibiting the inflammation induced by the P2Y12 receptor [45] . Wong et al have shown that PAR4 inhibition has the potential therapeutic advantage of antithrombotic activity with a low bleeding risk [46] . Interestingly, our predictions have revealed that proteinase-activated receptor 1 (PAR1) (gene name: F2R) is one of the potential targets of aspirin, whereas PAR1 inhibitors/antagonists appear to increase the risk of bleeding significantly [47] . Further experiments are required to validate these predictions. Therefore, the clinical studies performed in this work combined with computational system pharmacology mapping should be meaningful for assessing the therapeutic potential of cilostazol as an aspirin alternative.
There are several limitations of this study. First, this was a single-center observational study, and the patient population was relatively limited. We could not attempt to justify the sample size, because there were no available data regarding cilostazol as an alternative to aspirin; moreover, patients who are intolerant to aspirin are uncommon. Second, we could not administer a higher dose of cilostazol (200 mg/d), because some patients may not tolerate that dose. The dose of cilostazol (100 mg/d) in the present study is the dose commonly used in our institution. Third, dual antiplatelet therapy with thienopyridine and aspirin is a standard treatment, whereas the use of cilostazol instead of aspirin is not a generally accepted treatment at present. Finally, because clopidogrel-PPI interaction is an ongoing controversy, we did not consider the influence of PPI. In our previous study [48] , we have found that the efficacy of clopidogrel is not associated with PPI use. As a result, to confirm that the methodology is a good approach for a particular group of patients would require extensive studies involving a large number of patient populations; we are addressing this goal in ongoing efforts. Regardless of these limitations, our studies compared cilostazol with aspirin, in contrast to previous studies, which have focused on the additional inhibition of platelet aggregation by cilostazol when co-administered with aspirin and clopidogrel [44] [45] [46] [47] . Therefore, these data warrant a larger scale prospective randomized controlled trial for patients with aspirin intolerance.
In conclusion, in this cohort of patients with aspirin intolerance undergoing coronary stent implantation, cilostazol was well tolerated and effective. Our results suggest that cilostazol may be a reasonable alternative to aspirin in patients after stent implantation.
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